We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Commentary · January 12, 2022

Reduced Neutralisation of SARS-CoV-2 Omicron B.1.1.529 Variant by Post-Immunisation Serum

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
Lancet 2021 Dec 20;[EPub Ahead of Print], W Dejnirattisai, RH Shaw, P Supasa, C Liu, AS Stuart, AJ Pollard, X Liu, T Lambe, D Crook, DI Stuart, J Mongkolsapaya, JS Nguyen-Van-Tam, MD Snape, GR Screaton

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading